glp 1 drugs news Medicare will now help pay for some GLP-1 drugs. Here's what to know The promises and pitfalls of

In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg

Semaglutide GLP-1 can increase the risk of MTC, which is a rare type of thyroid cancer

Through its dual insulinotropic and glucagonotropic effects on stabilizing glucose levels, GIP could provide a buffer against hyperglycemia when large amounts of glucose are consumed and mitigate reactive hypoglycemia, especially after meals with high fat content

Additionally, research into novel delivery technologies, such as microneedle patches and implantable devices, holds the potential to further enhance patient convenience and compliance, thereby expanding the market reach and attractiveness of GLP-1 receptor agonists

In comparison, lizard GLP-1 itself shares an 83% sequence identity to human GLP-1 (84) [ Figure 2 ]

Its convenience and efficacy make it a popular choice for those seeking significant results